AU2020259375A1 - Methods for treatment of subjects with psoriatic arthritis - Google Patents

Methods for treatment of subjects with psoriatic arthritis Download PDF

Info

Publication number
AU2020259375A1
AU2020259375A1 AU2020259375A AU2020259375A AU2020259375A1 AU 2020259375 A1 AU2020259375 A1 AU 2020259375A1 AU 2020259375 A AU2020259375 A AU 2020259375A AU 2020259375 A AU2020259375 A AU 2020259375A AU 2020259375 A1 AU2020259375 A1 AU 2020259375A1
Authority
AU
Australia
Prior art keywords
antibody
week
dose
patient
efficacy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2020259375A
Other languages
English (en)
Inventor
Kirti Wardhaman Ganorkar
Anil RAGHAVAN
Atul Mathuradas RAUT
Siu-Long Yao
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sun Pharmaceutical Industries Ltd
Original Assignee
Sun Pharmaceutical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=72837755&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2020259375(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sun Pharmaceutical Industries Ltd filed Critical Sun Pharmaceutical Industries Ltd
Publication of AU2020259375A1 publication Critical patent/AU2020259375A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2020259375A 2019-04-15 2020-04-15 Methods for treatment of subjects with psoriatic arthritis Pending AU2020259375A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
IN201921015050 2019-04-15
IN201921015050 2019-04-15
IN202021004422 2020-01-31
IN202021004422 2020-01-31
PCT/IB2020/053565 WO2020212874A1 (en) 2019-04-15 2020-04-15 Methods for treatment of subjects with psoriatic arthritis

Publications (1)

Publication Number Publication Date
AU2020259375A1 true AU2020259375A1 (en) 2021-10-28

Family

ID=72837755

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020259375A Pending AU2020259375A1 (en) 2019-04-15 2020-04-15 Methods for treatment of subjects with psoriatic arthritis

Country Status (16)

Country Link
US (1) US20220298233A1 (https=)
EP (1) EP3956357A4 (https=)
JP (2) JP7628962B2 (https=)
KR (1) KR20210140780A (https=)
CN (1) CN113825768A (https=)
AU (1) AU2020259375A1 (https=)
BR (1) BR112021020612A2 (https=)
CA (1) CA3143604A1 (https=)
IL (1) IL287213A (https=)
JO (1) JOP20210279A1 (https=)
MA (1) MA55729A (https=)
MX (1) MX2021012652A (https=)
MY (1) MY210310A (https=)
PH (1) PH12021552536A1 (https=)
SG (1) SG11202111056YA (https=)
WO (1) WO2020212874A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2024323792A1 (en) * 2023-08-11 2026-03-12 Innovent Biologics (Suzhou) Co., Ltd. Method for treating plaque psoriasis wherein subject previously receiving biologic therapy for plaque psoriasis switches to using anti-il23p19 antibody
AU2024338774A1 (en) * 2023-09-07 2026-03-26 Innovent Biologics (Suzhou) Co., Ltd. Method for treating moderate and severe psoriasis using recombinant anti-il-23p19 antibody
WO2026069253A1 (en) * 2024-09-30 2026-04-02 Sun Pharmaceutical Industries Limited Long term safety of tildrakizumab in psoriatic arthritis

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7807389B2 (en) * 2003-03-14 2010-10-05 University Of Rochester Methods and compositions related to joint inflammation diseases
EP2007426A4 (en) * 2006-04-10 2010-06-16 Abbott Biotech Ltd COMPOSITIONS FOR THE TREATMENT OF PSORIASTIC POLYARTHRITIS AND THEIR APPLICATIONS
AR065420A1 (es) * 2007-02-23 2009-06-03 Schering Corp Anticuerpos anti-il-23 p19 de ingenieria
CA2734919C (en) * 2008-08-27 2016-08-16 Schering Corporation Lyophilized formulations of engineered anti-il-23p19 antibodies
PE20141162A1 (es) * 2010-11-04 2014-09-18 Boehringer Ingelheim Int Anticuerpos anti-il-23
ES2729603T3 (es) * 2012-06-27 2019-11-05 Merck Sharp & Dohme Anticuerpos IL-23 antihumanos cristalinos
UA117466C2 (uk) * 2012-12-13 2018-08-10 Мерк Шарп Енд Доме Корп. СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19

Also Published As

Publication number Publication date
MY210310A (en) 2025-09-10
JP2022529266A (ja) 2022-06-20
US20220298233A1 (en) 2022-09-22
EP3956357A1 (en) 2022-02-23
BR112021020612A2 (pt) 2021-12-28
JP2025069284A (ja) 2025-04-30
KR20210140780A (ko) 2021-11-23
PH12021552536A1 (en) 2022-07-04
CN113825768A (zh) 2021-12-21
MA55729A (fr) 2022-02-23
JP7628962B2 (ja) 2025-02-12
JOP20210279A1 (ar) 2021-10-14
EP3956357A4 (en) 2023-01-04
SG11202111056YA (en) 2021-11-29
WO2020212874A1 (en) 2020-10-22
IL287213A (en) 2021-12-01
CA3143604A1 (en) 2020-10-22
MX2021012652A (es) 2022-01-24

Similar Documents

Publication Publication Date Title
US20240376210A1 (en) Vedolizumab for the treatment of fistulizing crohn's disease
US20250066466A1 (en) Methods of treating non-radiographic axial spondyloarthritis using interleukin-17 (il-17) antagonists
JP2025069284A (ja) 乾癬性関節炎に罹患している対象者の治療方法
RU2723047C2 (ru) Средство для лечения множественной миеломы (ММ)
RU2697383C2 (ru) Применение антагонистов il-17 для торможения прогрессирования структурных повреждений у пациентов с псориатическим артритом
EP4469154A1 (en) Methods for treatment of subjects with plaque psoriasis of the scalp
US20240059783A1 (en) Anti-ox40 antagonistic antibodies and dosage for the treatment of ox40-mediated disorders
CN112689512B (zh) 用于治疗银屑病的组合物和方法
US20230331834A1 (en) Method of treating tendinopathy using interleukin-17 (il-17)
JP2026062653A (ja) シェーグレン症候群の処置
US20250263476A1 (en) Dosage regimens for treating multifocal motor neuropathy (mmn)
WO2024112527A2 (en) Methods for the treatment of thyroid eye disease
AU2023270497A1 (en) Methods of selectively treating tendinopathy using interleukin-17 (il-17) antagonists
RU2852738C1 (ru) Способы лечения аутоиммунных заболеваний с применением антагонистов интерлейкина-17 (il-17)
EP3952993B1 (en) Method of treating fumaric acid ester-resistant plaque psoriasis
WO2025146509A1 (en) Methods of treating multifocal motor neuropathy (mmn)
HK40117117A (zh) 用於治疗多灶性运动神经病(mmn)的给药方案
WO2025099576A1 (en) Compositions and methods for treating rheumatoid arthritis
WO2024077113A1 (en) Methods of treating fatigue in ulcerative colitis
EA052604B1 (ru) Схемы лечения мультифокальной моторной нейропатии (mmn)